- Home
- GMRE vs ENGN Comparison
GMRE vs ENGN Comparison
Compare GMRE & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMRE
- ENGN
- Stock Information
- Founded
- GMRE 2011
- ENGN 1999
- Country
- GMRE United States
- ENGN Canada
- Employees
- GMRE N/A
- ENGN N/A
- Industry
- GMRE Real Estate Investment Trusts
- ENGN
- Sector
- GMRE Real Estate
- ENGN
- Exchange
- GMRE Nasdaq
- ENGN Nasdaq
- Market Cap
- GMRE 428.4M
- ENGN 379.3M
- IPO Year
- GMRE N/A
- ENGN N/A
- Fundamental
- Price
- GMRE $32.30
- ENGN $8.25
- Analyst Decision
- GMRE Buy
- ENGN Buy
- Analyst Count
- GMRE 3
- ENGN 7
- Target Price
- GMRE $47.92
- ENGN $20.29
- AVG Volume (30 Days)
- GMRE 213.6K
- ENGN 377.8K
- Earning Date
- GMRE 11-04-2025
- ENGN 09-11-2025
- Dividend Yield
- GMRE 9.33%
- ENGN N/A
- EPS Growth
- GMRE N/A
- ENGN N/A
- EPS
- GMRE 0.34
- ENGN N/A
- Revenue
- GMRE $141,896,000.00
- ENGN N/A
- Revenue This Year
- GMRE $8.69
- ENGN N/A
- Revenue Next Year
- GMRE $5.10
- ENGN N/A
- P/E Ratio
- GMRE $95.82
- ENGN N/A
- Revenue Growth
- GMRE 2.95
- ENGN N/A
- 52 Week Low
- GMRE $30.09
- ENGN $2.65
- 52 Week High
- GMRE $47.45
- ENGN $9.85
- Technical
- Relative Strength Index (RSI)
- GMRE 71.95
- ENGN 56.24
- Support Level
- GMRE $31.32
- ENGN $7.62
- Resistance Level
- GMRE $32.21
- ENGN $9.65
- Average True Range (ATR)
- GMRE 0.79
- ENGN 0.88
- MACD
- GMRE -0.85
- ENGN -0.14
- Stochastic Oscillator
- GMRE 79.78
- ENGN 55.52
About GMRE Global Medical REIT Inc.
Global Medical REIT Inc is engaged predominantly in the acquisition of purpose-built healthcare facilities and the leasing of those facilities to physician groups and regional and national healthcare systems. The company's principal business objective is to provide attractive, risk-adjusted returns to its stockholders through a combination of reliable dividends and long-term capital appreciation. Its healthcare facilities are located in secondary markets and suburbs of primary markets and are typically leased to single-tenants under triple-net leases.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.